{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:55:38Z","timestamp":1785200138382,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T00:00:00Z","timestamp":1329436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Reports"],"abstract":"<jats:p>Invasive fungal infections (IFI) are an important cause of morbidity, increased hospitalization and healthcare costs in critically ill or immunocompromised children. The mortality is comprised between 5 and 20%. In the last 2 decades, the epidemiology of candidemia has changed with an increase of episodes caused by non-Candida albicans species. Central venous catheter, diagnosis of malignancy, and receipt of either vancomycin or antimicrobials with activity against anaerobic organisms for &gt;3 days have been associated with the development of candidemia in the pediatric intensive care unit (PICU). Additional risk factors found in hematological patients were the diagnosis of aplastic anemia, performing an unrelated bone marrow or cord blood transplant, the occurrence of a graft versus host disease and the use of steroids. Early antifungal treatment is recommended to reduce mortality. In neutropenic patients, liposomal amphotericin B, an echinocandin (caspofungin, micafungin), and voriconazole are considered the best option especially for C. glabrata and C. krusei. Fluconazole remains a valid option for infection by Candida albicans in patients not exposed to fluconazole prophylaxis. Amphotericn B deoxycholate is generally not recommended because of its nephrotoxicity.<\/jats:p>","DOI":"10.4081\/pr.2012.e9","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T16:53:17Z","timestamp":1329929597000},"page":"e9","source":"Crossref","is-referenced-by-count":25,"title":["Epidemiology, Risk Factors, and Therapy of Candidemia in Pediatric Hematological Patients"],"prefix":"10.3390","volume":"4","author":[{"given":"Chiara","family":"Cugno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2012,2,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/496922","article-title":"The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis","volume":"41","author":"Zaoutis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.inf.0000078159.53132.40","article-title":"Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities","volume":"22","author":"Wisplinghoff","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1086\/313450","article-title":"The epidemiology of candidemia in two United States cities: results of a population based active surveillance","volume":"29","author":"Kao","year":"1999","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1128\/JCM.42.4.1519-1527.2004","article-title":"Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population based active surveillance program","volume":"42","author":"Hajjeh","year":"2004","journal-title":"J Clin Microbiol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ijantimicag.2004.08.007","article-title":"Trends in antifungal use and species distribution among Candida isolates in a large paediatric hospital","volume":"24","author":"Manno","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1164\/rccm.200207-682OC","article-title":"The epidemiology of severe sepsis in children in the United States","volume":"167","author":"Watson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/pbc.21868","article-title":"Invasive fungal infections in pediatric leukemia patients receiving fluconazole prophylaxis","volume":"52","author":"Kaya","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.mph.0000155861.38641.ca","article-title":"Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution","volume":"27","author":"Rosen","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.inf.0000220256.69385.2e","article-title":"Fungal infections in children with cancer: a prospective, multicenter surveillance study","volume":"25","author":"Castagnola","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/pbc.23005","article-title":"Invasive fungal infections in pediatric oncology","volume":"56","author":"Mor","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1086\/514580","article-title":"Risk factors for candidemia in a children's hospital","volume":"26","author":"MacDonald","year":"1998","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/sj.bmt.1705113","article-title":"Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation","volume":"36","author":"Dvorak","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1086\/655698","article-title":"Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention","volume":"51","author":"Zaoutis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1542\/peds.2008-2055","article-title":"Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients","volume":"123","author":"Blyth","year":"2009","journal-title":"Pediatrics"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1086\/599039","article-title":"Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry","volume":"48","author":"Horn","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/376906","article-title":"A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients","volume":"37","author":"Pappas","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"R222","DOI":"10.1186\/cc9365","article-title":"Third European Conference on Infections in Leukemia Group. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia","volume":"14","author":"Mikulska","year":"2010","journal-title":"Crit Care"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of can-didemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1345\/aph.1M139","article-title":"A clinical review of echinocandins in pediatric patients","volume":"44","author":"VandenBussche","year":"2010","journal-title":"Ann Pharmacother"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/13693780802262123","article-title":"Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan","volume":"47","author":"Ikeda","year":"2009","journal-title":"Med Mycol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/sj.jp.7211380","article-title":"Experience with caspofungin in the treatment of persistent fungemia in neonates","volume":"25","author":"Natarajan","year":"2005","journal-title":"J Perinatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1097\/01.inf.0000246844.42159.a0","article-title":"Efficacy and safety of caspofungin therapy in children with invasive fungal infections","volume":"25","author":"Merlin","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jac\/dkl009","article-title":"Treatment with caspofungin in immuno-compromised paediatric patients: a multi-centre survey","volume":"57","author":"Groll","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for the treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal ampho-tericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s10096-005-0024-8","article-title":"International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia","volume":"24","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"}],"container-title":["Pediatric Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/pr\/article\/viewFile\/3799\/3432","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.pagepress.org\/journals\/index.php\/pr\/article\/viewFile\/3799\/5624","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2036-7503\/4\/1\/e9\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T03:28:45Z","timestamp":1644463725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7503\/4\/1\/e9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,17]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1]]}},"alternative-id":["pr.2012.e9"],"URL":"https:\/\/doi.org\/10.4081\/pr.2012.e9","relation":{},"ISSN":["2036-7503"],"issn-type":[{"value":"2036-7503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,17]]}}}